Test2LearnTM Community-based Pharmacogenomics Certificate Program

Program Information

The National Association of Chain Drug Stores is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The home study portion of the program is approved for 12 contact hours and the live training is approved for 8 contact hours of continuing pharmacy education credit. Credit is only awarded for completion of the entire 20 contact hour program. Credit must be claimed within 60 days of completing the program.

Practice-based Community Pharmacy-Based Point-of-Care Testing Certificate ACPE University Activity #0206-0000-16-012-B04-P.

Activity Type: Practice-based

Target Audience: Pharmacists in all practice settings

Release Date: September 26, 2016

Expiration Date: September 26, 2019

Target Audience

This course enables community pharmacists and members of academia, industry and government to learn the principles of pharmacogenomics by using real genetic data in a highly-interactive exercise. While discovering the practical implications of pharmacogenomics in disease states, participants will train to decipher tests, translate results, and make appropriate recommendations to help optimize patient medication regimens.

Claiming Credit

Continuing pharmacy education (CPE) credit will be awarded for the certificate training course only. This is a practice-based activity and is primarily constructed to instill, expand or enhance practice competencies through the systematic achievement of specified knowledge, skills, attitudes and perfomance behaviors.

Successful completion of the live seminar component involves passing the final exam with a grade of 80 percent or higher and demonstrating proficiency in diagnostic testing techniques. Successful completion of this component will result in 8.0 contact hours of continuing pharmacy education credit. Successful completion of the self-study component involves passing the self-study assessment questions with a grade of 80 percent or higher and will result in 12.0 contact hours of continuing pharmacy education. Attendance and participation are required before obtaining CPE credit. Partial credit will not be awarded.

CPE Monitor, a national, collaborative effort by ACPE and the National Association of Boards of Pharmacy (NABP) to provide an electronic system for pharmacists to track their completed PCE credits, went into effect on Jan. 1, 2013. NACDS, as an ACPE-accredited provider, is required to report pharmacist CPE credit using this new tracking system. Pharmacist participants must provide their NABP e-Profile identification number and date of birth (in MMDD format) when they register for a CPE activity. It will be the responsibility of the pharmacist to provide the correct information (i.e., e-Profile identification number and date of birth in MMDD format). If this information is not provided, NABP and ACPE prohibit NACDS from issuing CPE credit. Online access to their inventory of completed credits will allow pharmacists to easily monitor their compliance with CPE requirements and print statements of credit. Therefore, NACDS will not provide printed statements of credit to pharmacists. If you have not signed up for CPE Monitor, please go to MyCPEMonitor.net.  

Learning Objectives

At the completion of this activity, the participant will be able to:

  • Demonstrate understanding of basic genetic/genomic concepts and nomenclature
  • Describe advances in scientific knowledge and technology, which have led to innovations in personalized medicine
  • Identify the role of behavioral, social and environmental factors (lifestyle, socioeconomic factors, pollutants, among others) to modify or influence genetics in the manifestation of disease.
  • Compare and contrast different PGx study designs.
  • Identify drug- and disease-associated genetic variations that facilitate development of prevention and treatment strategies and appreciate there are differences in testing methodologies and are aware of the need to explore these differences in drug literature evaluation
  • Assess predisposition to disease and selection of drug treatment by using family history
  • Describe the role of genetic factors in maintaining health and preventing disease
  • Assess the difference between clinical diagnosis of disease and identification of genetic predisposition to disease (genetic variation is not strictly correlated with disease manifestation)
  • Recognize that pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g., the Apo E4 polymorphism)
  • Demonstrate an understanding of how genetic variation in a large number of proteins influences pharmacokinetics and pharmacodynamics related to pharmacologic effect and drug response
  • Use online resources to assign haplotypes and predicted drug response phenotypes from genetic data.
  • Describe the influence (or lack thereof) of ethnicity in genetic polymorphisms and associations of polymorphisms with drug response
  • Recognize the availability of evidence based guidelines that synthesize information relevant to genomic/pharmacogenomic tests and selection of drug therapy (e.g. Clinical pharmacogenomics implementation consortium)
  • Evaluate the availability of genetic testing under FDA, CLIA, and DTC regulations.
  • Evaluate PGx test reports through group-based activities and role-playing to demonstrate the PGx knowledge/skill-based competencies
  • Create a step-wise decision-making process for the integration of PGx with clinical variables known to impact PK/PD to make appropriate PGx-based recommendations for patients and populations.
  • List drugs/clinical situations where PGx testing is likely to be most useful clinically
  • Identify the potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
  • Describe the increased liability that accompanies access to detailed genomic patient information and maintain confidentiality and security
  • Define the cost, cost–effectiveness and reimbursement by insurers relevant to genomic or pharmacogenomic tests and test interpretation for patients and populations
  • Identify the need to refer a patient to a genetic specialist or genetic counselor
  • Describe proper documentation of test results in electronic patient record
  • Adopt a culturally sensitive and ethical approach to patient counseling regarding PGx test results
  • Demonstrate patient and provider communication about PGx testing and test results and counseling through group-based activities and role-playing
  • Evaluate about different business models to integrate PGx in various practice sites
  • Discuss different strategies to engage with local practitioners to optomize the delivery of PGx services prior to implementation
  • Demonstrate proficiency in different types of sample collection practices for PGx testing, review of safety procedures for handling biospecimens and proper mailing

© 2018 National Association of Chain Drug Stores, Inc.  All rights reserved.